Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.
In this episode, host Fraser Palamara explains why LTR Pharma (ASX:LTP) could shake up erectile dysfunction remedies.
The company shared news today its SPONTAN nasal spray treatment impressed in a bio-equivalence study – showing strong promise to disrupt the traditional PDE5 oral remedy market. The study demonstrated positive results in drug dosage and rate efficiency.
Tune in to get the latest.
The post Break it Down: LTR Pharma flexes SPONTAN spray success appeared first on Stockhead.
